The deluge of new cancer data to be revealed at ASCO has begun with Novartis and Roche both touting positive results for new therapies designed to fight tumors.
Novartis announced that a late-stage study of Sandostatin LAR demonstrated that it doubled the time without tumor growth in the mid-gut and cut the risk of disease progression by 67 percent. And mid-stage data on two drugs demonstrated their promise as a therapy for advanced melanoma. Almost three quarters of melanoma patients treated with a combination of Novartis' Afinitor--one of its most promising cancer programs--and Roche's Avastin demonstrated a clinical benefit.
Roche, meanwhile, unveiled new mid-stage data showing that one of its experimental therapies reduced the size of tumors in 25 percent of women with HER-2 positive breast cancer.
- read the report from Reuters